4//SEC Filing
Niklason Laura E 4
Accession 0001818382-25-000017
CIK 0001818382other
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 4:34 PM ET
Size
5.5 KB
Accession
0001818382-25-000017
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Niklason Laura E
DirectorPresident, CEO and Director
Transactions
- Award
Stock Options (right to buy)
2025-01-21+1,130,311→ 1,130,311 totalExercise: $4.56Exp: 2035-01-21→ Common Stock (1,130,311 underlying)
Footnotes (1)
- [F1]The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.
Documents
Issuer
Humacyte, Inc.
CIK 0001818382
Entity typeother
Related Parties
1- filerCIK 0001878075
Filing Metadata
- Form type
- 4
- Filed
- Jan 22, 7:00 PM ET
- Accepted
- Jan 23, 4:34 PM ET
- Size
- 5.5 KB